Literature DB >> 27314295

MicroRNA-181b inhibits glycolysis in gastric cancer cells via targeting hexokinase 2 gene.

Liang-Qing Li, Yang Yang, Hui Chen, Lin Zhang, Dun Pan, Wen-Jun Xie.   

Abstract

Cancer cells usually utilize glucose as a carbon source for aerobic glycolysis, which is named as ``Warburg effect''. Recent studies have shown that MicroRNAs (miRNAs), a class of short and non-coding RNAs, play a role in the regulation of metabolic reprograming in cancer cells. In the present study, we report that miR-181b negatively regulates glycolysis in gastric cancer cells. Over-expression of miR-181b mimics reduces the glucose uptake and lactate production, while increasing the cellular ATP levels in NCI-N87 and MGC80-3 cells. At the molecular level, miR-181b directly inhibits the expression level of hexokinase 2 (HK2), a key enzyme that catalyzes the first step of glycolysis, through targeting its 3'-untranslated region. In addition, miR-181b represses cell proliferation and migration and is dramatically down-regulated in human gastric cancers. Therefore, our data disclose a novel function of miR-181b in reprogramming the metabolic process in gastric cancer.

Entities:  

Keywords:  MicroRNA-181b; gastric cancer; glycolysis; hexokinase 2

Mesh:

Substances:

Year:  2016        PMID: 27314295     DOI: 10.3233/CBM-160619

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  19 in total

1.  MiR-125b-5p suppresses the bladder cancer progression via targeting HK2 and suppressing PI3K/AKT pathway.

Authors:  Shuo Liu; Qin Chen; Yue Wang
Journal:  Hum Cell       Date:  2019-10-11       Impact factor: 4.174

2.  Long Non-Coding RNA DUXAP8 Facilitates Cell Viability, Migration, and Glycolysis in Non-Small-Cell Lung Cancer via Regulating HK2 and LDHA by Inhibition of miR-409-3p.

Authors:  Dianhe Yin; Li Hua; Jiao Wang; Yuru Liu; Xiaoyan Li
Journal:  Onco Targets Ther       Date:  2020-07-22       Impact factor: 4.147

3.  MiR-323a-3p suppressed the glycolysis of osteosarcoma via targeting LDHA.

Authors:  Hanwen Chen; Shuming Gao; Cai Cheng
Journal:  Hum Cell       Date:  2018-08-07       Impact factor: 4.174

4.  Metformin alleviates nickel-induced autophagy and apoptosis via inhibition of hexokinase-2, activating lipocalin-2, in human bronchial epithelial cells.

Authors:  Yu-Ting Kang; Wen-Cheng Hsu; Chih-Hsien Wu; I-Lun Hsin; Pei-Ru Wu; Kun-Tu Yeh; Jiunn-Liang Ko
Journal:  Oncotarget       Date:  2017-11-06

5.  microRNA-23a promotes cell growth and metastasis in gastric cancer via targeting SPRY2-mediated ERK signaling.

Authors:  Yingjia Li; Hui Chen; Pengfei She; Ti Chen; Lihua Chen; Jinling Yuan; Botao Jiang
Journal:  Oncol Lett       Date:  2018-03-29       Impact factor: 2.967

6.  A positive feedback loop between miR-181b and STAT3 that affects Warburg effect in colon cancer via regulating PIAS3 expression.

Authors:  Xiaolin Pan; Jin Feng; Zhenhua Zhu; Linhua Yao; Shijie Ma; Bo Hao; Guoxin Zhang
Journal:  J Cell Mol Med       Date:  2018-07-28       Impact factor: 5.310

Review 7.  Micromanaging aerobic respiration and glycolysis in cancer cells.

Authors:  Ayla V Orang; Janni Petersen; Ross A McKinnon; Michael Z Michael
Journal:  Mol Metab       Date:  2019-02-06       Impact factor: 8.568

Review 8.  Metabolic reprogramming results in abnormal glycolysis in gastric cancer: a review.

Authors:  Yuanda Liu; Ze Zhang; Junyang Wang; Chao Chen; Xiaohuan Tang; Jiaming Zhu; Jingjing Liu
Journal:  Onco Targets Ther       Date:  2019-02-13       Impact factor: 4.147

Review 9.  Gastric Cancer Stem Cells: A Glimpse on Metabolic Reprogramming.

Authors:  Martina Addeo; Giuseppina Di Paola; Henu Kumar Verma; Simona Laurino; Sabino Russi; Pietro Zoppoli; Geppino Falco; Pellegrino Mazzone
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244

10.  MicroRNA-129-5p Regulates Glycolysis and Cell Proliferation by Targeting the Glucose Transporter SLC2A3 in Gastric Cancer Cells.

Authors:  Di Chen; Hui Wang; Jie Chen; Zhe Li; Shengli Li; Zhixiang Hu; Shenglin Huang; Yingjun Zhao; Xianghuo He
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.